Radiation Therapy for DCIS and Cardiovascular Disease Risk
Naomi B. Boekel, MSc, discusses the results from a large study that showed that radiation therapy for DCIS does not seem to increase cardiovascular disease risk.
Naomi B. Boekel, MSc, Netherlands Cancer Institute, Amsterdam, Netherlands, discusses the results from a large study that showed that radiation therapy for DCIS does not seem to increase cardiovascular disease risk.
There were two types of comparisons in this analysis, Boekel says. In part of the study, DCIS survivors had a similar risk of dying of any cause, but a 30 percent lower risk of dying from cardiovascular disease compared with the general population.
Clinical Pearls
Additionally, there was no increase in risk for cardiovascular disease between patients who received surgery alone compared with those that received surgery plus radiation (9% versus 8%), or between patients who received left- versus right-sided radiotherapy (7% versus 8%).
- DCIS survivors had a similar risk of dying of any cause, but a lower risk of dying from cardiovascular disease compared with the general population
- There was no increase in risk for cardiovascular disease between patients who received surgery alone versus those that received surgery plus radiation, or between patients who received left- versus right-sided radiotherapy
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
